Zacks: Analysts Anticipate IVERIC bio Inc (ISEE) Will Post Earnings of -$0.30 Per Share

Share on StockTwits

Equities research analysts expect that IVERIC bio Inc (NASDAQ:ISEE) will announce earnings of ($0.30) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for IVERIC bio’s earnings. IVERIC bio reported earnings per share of ($0.37) in the same quarter last year, which suggests a positive year-over-year growth rate of 18.9%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, August 7th.

On average, analysts expect that IVERIC bio will report full year earnings of ($1.36) per share for the current year, with EPS estimates ranging from ($1.59) to ($1.12). For the next year, analysts expect that the business will report earnings of ($1.19) per share, with EPS estimates ranging from ($1.22) to ($1.16). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for IVERIC bio.

IVERIC bio (NASDAQ:ISEE) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06.

Several research analysts have recently commented on the company. Zacks Investment Research lowered IVERIC bio from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. ValuEngine lowered IVERIC bio from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st.

Shares of NASDAQ ISEE traded down $0.02 during midday trading on Friday, reaching $1.32. 13,005 shares of the stock were exchanged, compared to its average volume of 225,536. The stock has a market capitalization of $55.99 million, a price-to-earnings ratio of -0.80 and a beta of 1.47. IVERIC bio has a twelve month low of $1.02 and a twelve month high of $4.50.

In related news, insider Glenn Sblendorio acquired 25,000 shares of IVERIC bio stock in a transaction that occurred on Friday, May 10th. The shares were purchased at an average cost of $1.48 per share, for a total transaction of $37,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.30% of the stock is currently owned by insiders.

About IVERIC bio

IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).

Read More: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on IVERIC bio (ISEE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Stock Traders Buy Large Volume of Boingo Wireless Call Options
Stock Traders Buy Large Volume of Boingo Wireless Call Options
Texas Roadhouse Sees Unusually Large Options Volume
Texas Roadhouse Sees Unusually Large Options Volume
Diebold Nixdorf Inc  Receives $6.00 Consensus Price Target from Brokerages
Diebold Nixdorf Inc Receives $6.00 Consensus Price Target from Brokerages
PennyMac Mortgage Investment Trust  Declares $0.47 Quarterly Dividend
PennyMac Mortgage Investment Trust Declares $0.47 Quarterly Dividend
WillScot Corp  Receives $16.79 Average Target Price from Brokerages
WillScot Corp Receives $16.79 Average Target Price from Brokerages
Jay T. Scripter Sells 25,758 Shares of Trex Company Inc  Stock
Jay T. Scripter Sells 25,758 Shares of Trex Company Inc Stock


© 2006-2019 Ticker Report